Taipei Exchange - Delayed Quote TWD

Enimmune corporation (6564.TWO)

Compare
26.80
-0.15
(-0.56%)
At close: 2:58:02 PM GMT+8

Key Executives

Enimmune corporation

No. 3, Section 1
Tanxing Road Tanzi District
Taichung City
Taiwan
886 4 2536 0925 https://www.enimmune.com.tw
Sector: 
Healthcare
Industry: 
Biotechnology

Description

Enimmune corporation operates as a biopharmaceutical Research and development, and marketing company in Taiwan. Its products include Tuberculin PPD RT23 SSI, an approved drug for tuberculin test to determine whether the patient is infected with tuberculosis. The company is also involved in the development of vaccines to prevent various infectious diseases, such as enterovirus, pneumonia, norovirus, dengue fever virus, Middle East respiratory syndrome coronavirus, etc. Enimmune corporation was founded in 2014 and is based in Taichung City, Taiwan.

Corporate Governance

Enimmune corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

Related Tickers